Prescient, a Bridgepoint-backed pricing and market access consultancy, has acquired Dolon, a London-based specialist in value and pricing for pharmaceutical and biotech companies. The deal strengthens Prescient's capabilities in rare diseases and oncology consulting, combining Dolon's expertise with Prescient's established teams. Dolon will operate as a dedicated value, pricing, and access practice within the expanded group.

Bridgepoint Development Capital partnered with Prescient in 2021, backing the consultancy's growth strategy in the healthcare sector. The acquisition of Dolon represents Prescient's latest move to consolidate market access capabilities, bringing together two London-based consultancies with complementary strengths. Dolon's team will retain its specialist focus while integrating with Prescient's broader operations.

The merger creates a more comprehensive offering for pharmaceutical clients navigating complex pricing and reimbursement landscapes. By combining resources, the enlarged entity can better serve the growing demand for market access expertise in rare disease treatments and oncology therapies. The deal positions Prescient to capture increased consulting opportunities as pharmaceutical companies face mounting pressure to demonstrate value in healthcare systems worldwide.